Live feed06:00:00·637dPRReleasevia QuantisnowIDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal MelanomaByQuantisnow·Wall Street's wire, on your screen.IDYA· IDEAYA Biosciences Inc.Health Care
